

From: bounce-124526392-85347729@list.cornell.edu on behalf of [Research Development at Cornell University](#)
To: [CU-RES-ADMIN-L](#)
Subject: Funding Opportunities: DoD Office of Congressionally Directed Medical Research Programs (CDMRP)
Date: Monday, April 6, 2020 2:39:16 PM

To members of the Cornell University community,

The Department of Defense (DoD) has recently announced anticipation FY20 funding opportunities for several programs managed by the Office of Congressionally Directed Medical Research Programs (CDMRP). The FY20 Defense Appropriations Act is anticipated to provide funding to support innovative, high-impact research in a number of different programs, including those listed below. For more information about each program (including guidelines and specific deadlines), please follow the provided links. Information about additional CDMRP funding opportunities not listed here can be found at: <https://cdmrp.army.mil/funding/default>

Autism Research Program (ARP)

\$15M appropriation to provide support for research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (ASD).

<https://cdmrp.army.mil/funding/arp>

Bone Marrow Failure Research Program (BMFRP)

\$3M appropriation to provide support for research of exceptional scientific merit and innovation with high impact that focuses on BMF diseases. <https://cdmrp.army.mil/funding/bmfrp>

Epilepsy Research Program (ERP)

\$12M appropriation to understand the causative links between traumatic brain injury (TBI) and epilepsy so that post-traumatic epilepsy (PTE) will be both preventable and treatable. <https://cdmrp.army.mil/pubs/press/2020/20erppreann>

Gulf War Illness Research Program (GWIRP)

\$22M appropriation to support research addressing Gulf War Illness (GWI) pathobiology, diagnosis, and treatment. <https://cdmrp.army.mil/funding/gwirp>

Hearing Restoration Research Programs

\$10M appropriation <https://cdmrp.army.mil/pubs/press/2020/20hrrppreann>

Kidney Cancer Research Program (KCRP)

\$40M appropriation <https://cdmrp.army.mil/pubs/press/2020/20kcrppreann>

Lung Cancer Research Program (LCRP)

\$14M appropriation <https://cdmrp.army.mil/funding/lcrp>

Melanoma Research Program (MRP)

\$20M appropriation <https://cdmrp.army.mil/pubs/press/2020/20mrppreann>

Military Burn Research Program (MBRP)

\$10M appropriation to support a research portfolio in the treatment of burns and the trauma associated with burn injuries sustained during combat or combat-related activities. Outcomes of successful research are anticipated to benefit Service members, Veterans, and the general public. <https://cdmrp.army.mil/funding/mbrp>

Neurofibromatosis Research Program (NFRP)

\$15M appropriation. NFRP encourages applications that specifically address the critical needs of the NF community in one or more of the FY20 Areas of Emphasis: <https://cdmrp.army.mil/funding/nfrp>

Orthotics and Prosthetics Outcomes Research Program (OPORP)

\$15M appropriation to support research on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology. OPORP supports research that evaluates orthoses and/or prostheses using patient-centric outcomes relevant to Service members and Veterans with limb loss and/or limb impairment. The intent of this research is to generate clinically useful evidence that will enhance and optimize patient outcomes. <https://cdmrp.army.mil/funding/oporp>

Ovarian Cancer Research Program (OCRP)

\$35M appropriation to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service members, Veterans, retirees, their family members, and all women impacted by this disease. <https://cdmrp.army.mil/funding/ocrp>

Peer Reviewed Cancer Research Program (PRCRP)

\$110M appropriation to provide funds for research into cancers *not* addressed in the breast, pancreatic, prostate, ovarian, kidney, lung, melanoma, and rare cancer research programs. To be considered for funding, applications for the FY20 PRCRP *must* address at least one of the FY20 PRCRP Topic Areas as directed by Congress. Research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, melanoma, pancreatic, rare cancer, or ovarian cancer will *not* be accepted. <https://cdmrp.army.mil/funding/prcrp>

Peer Reviewed Medical Research Program (PRMRP)

\$360M appropriation to support to support medical research projects of clear scientific merit and direct relevance to military health. <https://cdmrp.army.mil/funding/prmrp>

Peer Reviewed Orthopaedic Research Program (PRORP)

\$30M appropriation to support innovative, high-impact, clinically-relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries. <https://cdmrp.army.mil/funding/oporp>

Prostate Cancer Research Program (PCRP)

\$110M appropriation to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease. <https://cdmrp.army.mil/funding/pcrp>

Spinal Cord Injury Research Program (SCIRP)

\$40M appropriation to support spinal cord injury (SCI) research.

<https://cdmrp.army.mil/funding/scirp>

Tick-Borne Disease Research Program (TBDRP)

\$7M appropriation <https://cdmrp.army.mil/funding/tbdrp.aspx>

Tuberous Sclerosis Complex Research Program (TSCRCP)

\$6M appropriation <https://cdmrp.army.mil/funding/tscrp>

The Fiscal Year 2020 (FY20) Defense Appropriations Bill has not been signed into law. The information is being provided to investigators time to plan and develop ideas for submission to the anticipated FY20 funding opportunities. *Pre-announcement should not be construed as an obligation by the Government.*